Cardiotonic Agents (Cardiac Stimulants)

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

Also Known As:

Networked: 139 relevant articles (16 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ebner, Annette: 2 articles (01/2015 - 01/2013)
2.	Ebner, Bernd: 2 articles (01/2015 - 01/2013)
3.	Weinbrenner, Christof: 2 articles (01/2015 - 01/2013)
4.	Strasser, Ruth H: 2 articles (01/2015 - 01/2013)
5.	Lange, Stefan A: 2 articles (01/2015 - 01/2013)
6.	Endoh, Masao: 2 articles (08/2013 - 05/2003)
7.	Miki, Takayuki: 2 articles (01/2012 - 11/2008)
8.	Miura, Tetsuji: 2 articles (01/2012 - 11/2008)
9.	Sykes, Brian D: 2 articles (04/2008 - 01/2004)
10.	Li, Monica X: 2 articles (04/2008 - 01/2004)

Related Diseases

1.	Heart Failure 01/01/1981 - "The achievement of satisfactory ambulatory therapy of severe chronic congestive heart failure may be helped by the development of safe and orally effective cardiotonic agents. " 11/01/2010 - "Comparative therapeutic efficacy of adenocin and non-glycoside cardiotonic drugs in chronic heart failure at rest and under conditions of heart overload." 08/01/1987 - "The therapeutic efficacy of cardiotonic drugs used in the treatment of ambulant heart failure patients should be evaluated with reference to the way they alter the relation between cardiac pumping reserve and exercise capacity." 11/01/1984 - "Cardiotonic agents may prove useful in the long-term treatment of chronic heart failure provided myocardial efficiency is enhanced and clinical status is improved. " 12/01/1989 - ""Cardiotonic Drugs in the Management of Chronic Congestive Heart Failure: Digitalis Revisited "."
2.	Neoplasms (Cancer) 01/01/2011 - "The objective of this review was to assess the efficacy of different cardioprotective agents in preventing heart damage in cancer patients treated with anthracyclines. " 01/01/2008 - "The objective of this review was to assess the efficacy of different cardioprotective agents in preventing heart damage in cancer patients treated with anthracyclines. " 01/01/2005 - "The objective of this review was to assess the efficacy of different cardioprotective agents in preventing heart damage in cancer patients treated with anthracyclines. " 01/01/2006 - "Natural products such as resveratrol have gained considerable attention as cancer chemopreventive or cardioprotective agents and also because of their antitumor properties. " 01/01/2009 - "In this review we also discuss recent developments in: a) the molecular mechanisms underlying anthracycline-induced cardiotoxicity; b) the role of cytosolic NADPH-dependent reductases in anthracycline metabolism; c) the influence of genetic polymorphisms on cardiotoxicity outcome; d) the perspectives on the most promising strategies for limiting or preventing anthracycline-induced cardiotoxicity, focusing on controversial aspects and on recent data regarding analogues of the natural compounds, tumor-targeted formulations and cardioprotective agents."
3.	Cardiomyopathies (Cardiomyopathy) 01/01/2007 - "Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents." 01/01/1984 - "The main lines of research are aimed at improving our understanding of the mechanism of the cardiomyopathy, the institution of clinical trials to detect the first signs of toxicity of continuous infusions, the improvement of the standardisation and specificity of methods of detection, better definition of alarm thresholds and the development of new, less cardiotoxic, anthracyclines and cardioprotective agents." 07/01/1987 - "Mild isoprenaline overload and hereditary cardiomyopathy both are forms of heart failure which are presumably not associated with a lack of activator Ca. It is concluded that cardiotonic agents increasing the cardiac myofibrillar sensitivity to Ca ions would be beneficial in both cases, representing a phenomenologically causative treatment in hearts failing due to isoprenaline pretreatment. "
4.	Coronary Occlusion 06/01/2007 - "There are numerous differences between the experimental models and clinical studies, including the fact that experimental studies typically use abrupt occlusion and reperfusion protocols in animals with previously healthy myocardium that apparently do not predict the therapeutic efficacy of novel cardioprotective agents in a clinical setting with pre-existing progressive coronary disease, intermittent coronary occlusion, and relatively late reperfusion. "
5.	Coronary Disease (Coronary Heart Disease) 06/01/2007 - "There are numerous differences between the experimental models and clinical studies, including the fact that experimental studies typically use abrupt occlusion and reperfusion protocols in animals with previously healthy myocardium that apparently do not predict the therapeutic efficacy of novel cardioprotective agents in a clinical setting with pre-existing progressive coronary disease, intermittent coronary occlusion, and relatively late reperfusion. "

Related Drugs and Biologics

1.	Anthracyclines
2.	Diuretics
3.	pimobendan
4.	Sodium
5.	Isoproterenol (Isoprenaline)
6.	Ions
7.	Hydrogen
8.	Cromakalim (Levcromakalim)
9.	Carbon Monoxide
10.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)

Related Therapies and Procedures

1.	Resuscitation
2.	Drug Therapy (Chemotherapy)
3.	Induced Heart Arrest (Cardioplegia)
4.	Angioplasty (Angioplasty, Transluminal)
5.	Intra-Arterial Infusions